Tsung-Hsing Hung1,2,3, Chen-Chi Tsai2,4, Chung-Chi Lin3, Hsing-Feng Lee3, Chi-Jen Chu5, Han-Chieh Lin3. 1. Division of Gastroenterology, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan, Republic of China. 2. School of Medicine, Tzu Chi University, Hualien, Taiwan, Republic of China. 3. Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, and National Yang-Ming School of Medicine, No-201, Sec 2, Shih-Pai Road, Taipei, Taiwan, 11217, Republic of China. 4. Division of Infectious Disease, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan, Republic of China. 5. Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, and National Yang-Ming School of Medicine, No-201, Sec 2, Shih-Pai Road, Taipei, Taiwan, 11217, Republic of China. cjchu@vghtpe.gov.tw.
Abstract
PURPOSE: Diffuse infiltrative hepatocellular carcinoma (D-HCC) is an incurable disease with short survival time. Transarterial chemoembolization (TACE) was often used to alleviate patient's symptoms and reduce tumor burden. However, it remains unknown if the TACE benefits the survival of D-HCC patients. METHODS: A hospital-based retrospective study was conducted at a large referral hospital in Taiwan for a 9-year period (2000-2008). RESULTS: Of the 150 D-HCC patients, 106 patients were related to hepatitis B virus (HBV), 17 to hepatitis C virus (HCV), 3 to both HBV and HCV, and 24 not to HBV or HCV. Multivariate Cox regression analysis showed treatment strategy, serum alpha-fetoprotein level, model for end-stage liver disease (MELD) score, serum gamma glutamyl transferase, and serum lactic acid dehydrogenase were associated with survival time. Compared to supportive treatment, the adjusted hazard ratios of transarterial chemoembolization (TACE) and chemotherapy including oral or systemic chemotherapy were 0.383 (p < 0.001) and 0.711 (p = 0.289), respectively. CONCLUSION: TACE is a preferred therapy for D-HCC patients.
PURPOSE: Diffuse infiltrative hepatocellular carcinoma (D-HCC) is an incurable disease with short survival time. Transarterial chemoembolization (TACE) was often used to alleviate patient's symptoms and reduce tumor burden. However, it remains unknown if the TACE benefits the survival of D-HCC patients. METHODS: A hospital-based retrospective study was conducted at a large referral hospital in Taiwan for a 9-year period (2000-2008). RESULTS: Of the 150 D-HCC patients, 106 patients were related to hepatitis B virus (HBV), 17 to hepatitis C virus (HCV), 3 to both HBV and HCV, and 24 not to HBV or HCV. Multivariate Cox regression analysis showed treatment strategy, serum alpha-fetoprotein level, model for end-stage liver disease (MELD) score, serum gamma glutamyl transferase, and serum lactic acid dehydrogenase were associated with survival time. Compared to supportive treatment, the adjusted hazard ratios of transarterial chemoembolization (TACE) and chemotherapy including oral or systemic chemotherapy were 0.383 (p < 0.001) and 0.711 (p = 0.289), respectively. CONCLUSION: TACE is a preferred therapy for D-HCC patients.
Entities:
Keywords:
Diffuse infiltrative type; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Transarterial chemoembolization
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: Sun-Jung Myung; Jung-Hwan Yoon; Kang Mo Kim; Geum-Youn Gwak; Yoon Jun Kim; Ji-Won Yu; Jin Wook Chung; Hyo-Suk Lee Journal: Hepatogastroenterology Date: 2006 Mar-Apr
Authors: H Oka; A Saito; K Ito; T Kumada; S Satomura; H Kasugai; Y Osaki; T Seki; M Kudo; M Tanaka Journal: J Gastroenterol Hepatol Date: 2001-12 Impact factor: 4.029
Authors: Sang Hoon Jeon; Kyung Sik Park; Young Hwan Kim; Yo Sig Shin; Min Kyoung Kang; Byoung Kuk Jang; Woo Jin Chung; Kwang Bum Cho; Jae Seok Hwang Journal: Korean J Gastroenterol Date: 2007-09
Authors: T Livraghi; A Giorgio; G Marin; A Salmi; I de Sio; L Bolondi; M Pompili; F Brunello; S Lazzaroni; G Torzilli Journal: Radiology Date: 1995-10 Impact factor: 11.105